Company Registration No. SC665433 (Scotland)
DOW DRUG DEVELOPMENT SOLUTIONS LIMITED
Annual Report and Statement of Accounts
For the Period from 01 July 2022 to 30 June 2023

DOW DRUG DEVELOPMENT SOLUTIONS LIMITED

Annual report and statement of accounts for the period ending 30/06/2023

DOW DRUG DEVELOPMENT SOLUTIONS LIMITED

Financial statement for the period ended 30/06/2023

Company Information

1 Statutory Information
Company Number SC665433
Registered Office 1 CRAIGLOCKHART PARK
EDINBURGH
EH14 1ER
2 Directors
Directors who held office during the period were:
Margaret Sara DOW   
Robert James DOW   
3 Principal Activity
The principal activity of the company is providing consultancy activities to the drug industry.
4 Employees
Average number of employees, including directors, during the year was as follows:
2023 2
2022 2

DOW DRUG DEVELOPMENT SOLUTIONS LIMITED

Financial statement for the period ended 30/06/2023

Statement of Financial Position

2023 2022
£ £
Fixed Assets 964 2,199
Current Assets 117,134 118,866
Creditors: amounts falling due within one year (21,819) (28,385)
Net Current Assets 95,315 90,481
Total assets less current liabilities 96,279 92,680
Creditors: amounts falling due after one year - -
Net Assets 96,279 92,680
Capital and reserves 96,279 92,680
For the period ending 30/06/2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
Approved by the Board on 31 October 2023
Margaret Dow
Company Registration No. SC665433